Harmaline tremor: underlying mechanisms in a potential animal model of essential tremor
- PMID: 23440018
- PMCID: PMC3572699
- DOI: 10.7916/D8TD9W2P
Harmaline tremor: underlying mechanisms in a potential animal model of essential tremor
Abstract
Background: Harmaline and harmine are tremorigenic β-carbolines that, on administration to experimental animals, induce an acute postural and kinetic tremor of axial and truncal musculature. This drug-induced action tremor has been proposed as a model of essential tremor. Here we review what is known about harmaline tremor.
Methods: Using the terms harmaline and harmine on PubMed, we searched for papers describing the effects of these β-carbolines on mammalian tissue, animals, or humans.
Results: Investigations over four decades have shown that harmaline induces rhythmic burst-firing activity in the medial and dorsal accessory inferior olivary nuclei that is transmitted via climbing fibers to Purkinje cells and to the deep cerebellar nuclei, then to brainstem and spinal cord motoneurons. The critical structures required for tremor expression are the inferior olive, climbing fibers, and the deep cerebellar nuclei; Purkinje cells are not required. Enhanced synaptic norepinephrine or blockade of ionic glutamate receptors suppresses tremor, whereas enhanced synaptic serotonin exacerbates tremor. Benzodiazepines and muscimol suppress tremor. Alcohol suppresses harmaline tremor but exacerbates harmaline-associated neural damage. Recent investigations on the mechanism of harmaline tremor have focused on the T-type calcium channel.
Discussion: Like essential tremor, harmaline tremor involves the cerebellum, and classic medications for essential tremor have been found to suppress harmaline tremor, leading to utilization of the harmaline model for preclinical testing of antitremor drugs. Limitations are that the model is acute, unlike essential tremor, and only approximately half of the drugs reported to suppress harmaline tremor are subsequently found to suppress tremor in clinical trials.
Keywords: Tremor; animal model; cerebellum; harmaline; harmine; inferior olive.
Conflict of interest statement
Figures



Similar articles
-
The indolaminergic innervation of the inferior olive. 2. Relation to harmaline induced tremor.Brain Res. 1977 Aug 5;131(1):23-37. doi: 10.1016/0006-8993(77)90026-9. Brain Res. 1977. PMID: 884545
-
Effect of harmaline on cells of the inferior olive in the absence of tremor: differential response of genetically dystonic and harmaline-tolerant rats.Neuroscience. 1991;41(2-3):543-9. doi: 10.1016/0306-4522(91)90347-q. Neuroscience. 1991. PMID: 1870702
-
Harmaline induced tremor. III. A combined simple units, horseradish peroxidase, and 2-deoxyglucose study of the olivocerebellar system in the rat.Exp Brain Res. 1984;57(1):128-37. doi: 10.1007/BF00231139. Exp Brain Res. 1984. PMID: 6519221
-
Linking Essential Tremor to the Cerebellum-Animal Model Evidence.Cerebellum. 2016 Jun;15(3):285-98. doi: 10.1007/s12311-015-0750-0. Cerebellum. 2016. PMID: 26660708 Review.
-
Increased Purkinje Cell Complex Spike and Deep Cerebellar Nucleus Synchrony as a Potential Basis for Syndromic Essential Tremor. A Review and Synthesis of the Literature.Cerebellum. 2021 Apr;20(2):266-281. doi: 10.1007/s12311-020-01197-5. Epub 2020 Oct 13. Cerebellum. 2021. PMID: 33048308 Review.
Cited by
-
Pathogenesis of severe ataxia and tremor without the typical signs of neurodegeneration.Neurobiol Dis. 2016 Feb;86:86-98. doi: 10.1016/j.nbd.2015.11.008. Epub 2015 Nov 14. Neurobiol Dis. 2016. PMID: 26586559 Free PMC article.
-
Translational Pharmacology of PRAX-944, a Novel T-Type Calcium Channel Blocker in Development for the Treatment of Essential Tremor.Mov Disord. 2022 Jun;37(6):1193-1201. doi: 10.1002/mds.28969. Epub 2022 Mar 7. Mov Disord. 2022. PMID: 35257414 Free PMC article.
-
Cannabinoid type 1 receptor antagonism ameliorates harmaline-induced essential tremor in rat.Br J Pharmacol. 2016 Nov;173(22):3196-3207. doi: 10.1111/bph.13581. Epub 2016 Oct 4. Br J Pharmacol. 2016. PMID: 27545646 Free PMC article.
-
A Phase 2 Proof-of-Concept, Randomized, Placebo-Controlled Trial of CX-8998 in Essential Tremor.Mov Disord. 2021 Aug;36(8):1944-1949. doi: 10.1002/mds.28584. Epub 2021 Mar 25. Mov Disord. 2021. PMID: 33764619 Free PMC article. Clinical Trial.
-
Accurate Tracking of Locomotory Kinematics in Mice Moving Freely in Three-Dimensional Environments.eNeuro. 2025 Jun 25;12(6):ENEURO.0045-25.2025. doi: 10.1523/ENEURO.0045-25.2025. Print 2025 Jun. eNeuro. 2025. PMID: 40447413 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Other Literature Sources